scholarly journals Early Inhaled Nitric Oxide Therapy for Term and Near-Term Newborn Infants with Hypoxic Respiratory Failure: Neurodevelopmental Follow-Up

2007 ◽  
Vol 150 (3) ◽  
pp. 235-240.e1 ◽  
Author(s):  
G. Ganesh Konduri ◽  
Betty Vohr ◽  
Charlene Robertson ◽  
Gregory M. Sokol ◽  
Alfonso Solimano ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Newborn Infants ◽  
Inhaled Nitric Oxide ◽  
Term Newborn ◽  
Hypoxic Respiratory Failure ◽  
Near Term ◽  
Nitric Oxide Therapy

Target versus actual oxygenation index at initiation of inhaled nitric oxide in neonates with hypoxic respiratory failure: survey results from 128 patient cases

2014 ◽  
Vol 42 (6) ◽  
Author(s):  
Sergio Golombek ◽  
Denise Suttner ◽  
Reuben Ehrlich ◽  
Jim Potenziano
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Oxygenation Index ◽  
Inhaled Nitric Oxide ◽  
Hypoxic Respiratory Failure ◽  
Patient Groups ◽  
Survey Results ◽  
Fraction Of Inspired Oxygen ◽  
Inspired Oxygen

AbstractInhaled nitric oxide (iNO) is a well-established treatment for neonatal hypoxic respiratory failure (HRF). However, iNO therapy initiation criteria have not been standardized. This report describes a follow-up survey administered to neonatologists who had completed an Awareness, Trial, and Usage Survey. The objectives were to compare stated target oxygenation index (OI) versus actual OI at which iNO is initiated in respondents’ patients and identify factors associated with iNO initiation at other levels.Neonatologists provided iNO-treated HRF patient data. Target and actual OI at initiation were determined. Patient groups were stratified by actual OI deviation from target [<4; at (±3); above: 4–10, 11–20, >20; not measured]. Reasons for above-target OI were determined.Of 83 invited neonatologists, 26 (31%) participated, providing data for 128 patients; 85/128 patients (66%) had OI measured at initiation with neonatologist-stated mean target OI 18.8±5.8. Actual mean OI was 26.2±10.3. iNO was initiated ≤ target in 30/85 patients (35%); most [55/85 (65%)] had iNO initiated when OI was above target. Patients aged ≤1 day and those receiving a fraction of inspired oxygen (FiOAmong surveyed neonatologists who treat infants with HRF with pulmonary hypertension (PH), there is a disparity between stated target versus actual OI for iNO initiation, particularly among infants <1 day old and those receiving FiO

Cost-effectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: Eighteen- to 24-month follow-up for Canadian patients

2002 ◽  
Vol 30 (10) ◽  
pp. 2330-2334 ◽  
Author(s):  
Philip Jacobs ◽  
Neil N. Finer ◽  
Konrad Fassbender ◽  
Ed Hall ◽  
Charlene M. T. Robertson
Keyword(s):  
Nitric Oxide ◽  
Cost Effectiveness ◽  
Respiratory Failure ◽  
Inhaled Nitric Oxide ◽  
Term Infants ◽  
Near Term

scholarly journals Inhaled Nitric Oxide and Hypoxic Respiratory Failure in Term Infants: Neurodevelopmental Follow-Up

1999 ◽  
Vol 45 (4, Part 2 of 2) ◽  
pp. 196A-196A ◽  
Author(s):  
Neil N Finer ◽  
Betty R Vohr ◽  
Charlene M Robertson ◽  
Joel Verter ◽  
Linda L Wright ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Inhaled Nitric Oxide ◽  
Term Infants ◽  
Hypoxic Respiratory Failure

Inhaled Nitric Oxide Therapy in the Near-Term or Term Neonate with Hypoxic Respiratory Failure

2004 ◽  
Vol 23 (1) ◽  
pp. 5-13 ◽  
Author(s):  
Leslie Williams ◽  
Thomas Shaffer ◽  
Jay Greenspan
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Vascular Reactivity ◽  
Minute Ventilation ◽  
Strong Relationship ◽  
Inhaled Nitric Oxide ◽  
Term Infants ◽  
Arterial Blood ◽  
Hypoxic Respiratory Failure ◽  
Near Term

Inhaled nitric oxide (iNO) has altered the management strategy for treating near-term and term infants with hypoxic respiratory failure (HRF) There is a strong relationship between HRF and persistent pulmonary hypertension of the newborn (PPHN). PPHN is characterized by elevated pulmonary resistance, pulmonary vasoconstriction, and altered vascular reactivity. The resulting high pulmonary pressure may lead to HRF, which is defined as a relative deficiency of oxygen in arterial blood and insufficient minute ventilation. iNO improves oxygenation and decreases the need for extracorporeal membrane oxygenation. Although iNO therapy is effective, its efficacy can depend on the fine points of its use and on other care the infant is receiving. Even in NICUs that do not have iNO available, those who care for term infants with HRF must be familiar with its use and know when and how to transfer these infants and how to help families through this difficult period. Because iNO therapy will probably be used more frequently in nurseries over the next few years, more information on the safety and efficacy of its use in the broader neonatal population needs to be available.

scholarly journals Efficacy of inhaled nitric oxide in neonates with hypoxic respiratory failure and pulmonary hypertension: the Japanese experience

2018 ◽  
Vol 46 (6) ◽  
pp. 657-663 ◽  
Author(s):  
Satoshi Suzuki ◽  
Hajime Togari ◽  
Jim L. Potenziano ◽  
Michael D. Schreiber
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Respiratory Failure ◽  
Negative Impact ◽  
Survival Rates ◽  
Oxygenation Index ◽  
Inhaled Nitric Oxide ◽  
Preterm Neonates ◽  
Therapeutic Trial ◽  
Hypoxic Respiratory Failure

AbstractObjective:To analyze data from a registry of Japanese neonates with hypoxic respiratory failure associated with pulmonary hypertension (PH) to compare the effectiveness of inhaled nitric oxide (iNO) in neonates born <34 weeks vs. ≥34 weeks gestational age (GA).Materials and methods:iNO was administered according to approved Japanese product labeling. Study data were collected before iNO administration and at predefined intervals until discontinuation.Results:A total of 1,114 neonates were included (n=431, <34 weeks GA; n=675, ≥34 weeks GA; n=8, missing age data). Mean decrease from baseline oxygenation index (OI) was similar in both age groups. OI reduction was more pronounced in the <34 weeks subgroups with baseline OI ≥25. Survival rates were similar in the <34 weeks GA and ≥34 weeks GA groups stratified by baseline OI (OI<15, 89% vs. 93%; 15≤OI<25, 85% vs. 91%; 25≤OI≤40, 73% vs. 79%; OI>40, 64% vs. 66%).Conclusion:iNO improved oxygenation in preterm neonates as effectively as in late preterm and term neonates, without negative impact on survival. If clinically significant PH is present, as measured by pulse oximetry or echocardiography, a therapeutic trial of iNO might be indicated for preterm neonates.

Sign in / Sign up

Export Citation Format

Share Document